Literature DB >> 28934451

Acute malaria infection after atovaquone-proguanil prophylaxis.

Anna A Minta1,2, Kathrine R Tan2, Kimberly E Mace2, Paul M Arguin2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28934451      PMCID： PMC5609460          DOI： 10.1093/jtm/taw080

Source DB:  PubMed          Journal:  J Travel Med        ISSN： 1195-1982            Impact factor:   8.490


× No keyword cloud information.
  5 in total

1.  Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model.

Authors:  Gregory A Deye; R Scott Miller; Lori Miller; Carola J Salas; Donna Tosh; Louis Macareo; Bryan L Smith; Susan Fracisco; Emily G Clemens; Jittawadee Murphy; Jason C Sousa; J Stephen Dumler; Alan J Magill
Journal:  Clin Infect Dis       Date:  2011-11-03       Impact factor: 9.079

2.  Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II).

Authors:  Andrea K Boggild; Monica E Parise; Linda S Lewis; Kevin C Kain
Journal:  Am J Trop Med Hyg       Date:  2007-02       Impact factor: 2.345

3.  Effectiveness of twice a week prophylaxis with atovaquone-proguanil (Malarone®) in long-term travellers to West Africa.

Authors:  Tamar Lachish; Maskit Bar-Meir; Neta Eisenberg; Eli Schwartz
Journal:  J Travel Med       Date:  2016-09-13       Impact factor: 8.490

4.  Effectiveness of short prophylactic course of atovaquone-proguanil in travelers to sub-saharan Africa.

Authors:  Eyal Leshem; Eyal Meltzer; Shmuel Stienlauf; Eran Kopel; Eli Schwartz
Journal:  J Travel Med       Date:  2013-12-03       Impact factor: 8.490

5.  Novel Mutation in Cytochrome B of Plasmodium falciparum in One of Two Atovaquone-Proguanil Treatment Failures in Travelers Returning From Same Site in Nigeria.

Authors:  Mateusz M Plucinski; Curtis S Huber; Sheila Akinyi; Willard Dalton; Mary Eschete; Katharine Grady; Luciana Silva-Flannery; Blaine A Mathison; Venkatachalam Udhayakumar; Paul M Arguin; John W Barnwell
Journal:  Open Forum Infect Dis       Date:  2014-08-05       Impact factor: 3.835
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.